- Home
- SOWG vs BIVI Comparison
SOWG vs BIVI Comparison
Compare SOWG & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SOWG | BIVI |
|---|---|---|
| Founded | 2010 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1M | 10.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SOWG | BIVI |
|---|---|---|
| Price | $0.52 | $1.38 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 75.2K | 54.1K |
| Earning Date | 11-14-2025 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,270,357.00 | N/A |
| Revenue This Year | $6.81 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.47 | $1.25 |
| 52 Week High | $4.12 | $25.76 |
Technical Indicators
Market Signals| Indicator | SOWG | BIVI |
|---|---|---|
| Relative Strength Index (RSI) | 37.92 | 37.14 |
| Support Level | $0.47 | $1.40 |
| Resistance Level | $0.55 | $1.51 |
| Average True Range (ATR) | 0.05 | 0.10 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 20.85 | 2.94 |
Price Performance
Historical ComparisonAbout SOWG Sow Good Inc.
Sow Good Inc is engaged in manufacturing and marketing freeze-dried fruits, vegetables, snacks, smoothies, and soups. The company also sells gluten-free products under the Sow Good brand. The company is developing a freeze-dried candy market and snack manufacturing to provide consumers with flavorful freeze-dried treats.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.